| Not Yet Recruiting | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) NCT07460765 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) i NCT06398418 | Rise Therapeutics LLC | Phase 1 |
| Completed | How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions. NCT06654999 | Skin Analytics Limited | — |
| Active Not Recruiting | Study to Examine Lesions of the Skin Using Confocal Laser Microscopy NCT06598137 | LMU Klinikum | — |
| Unknown | Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer NCT05932511 | Center for Biomedical Research, Inc. | EARLY_Phase 1 |
| Unknown | Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study NCT05761132 | Leiden University Medical Center | Phase 2 |
| Active Not Recruiting | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advance NCT04391049 | NRG Oncology | Phase 1 |
| Recruiting | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers NCT03935893 | Udai Kammula | Phase 2 |
| Terminated | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors NCT04116320 | Craig L Slingluff, Jr | Phase 1 |
| Completed | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma NCT03370276 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | Using MC1R Genotype to Impact Melanoma Risk Behavior NCT03509467 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Terminated | Safety Study of SEA-CD40 in Cancer Patients NCT02376699 | Seagen Inc. | Phase 1 |
| Completed | Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Assoc NCT01721525 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy NCT01358097 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer NCT01384708 | Anandasabapathy, Sharmila, M.D. | EARLY_Phase 1 |
| Completed | Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer NCT01016769 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) NCT00705016 | Merck KGaA, Darmstadt, Germany | Phase 1 / Phase 2 |
| Completed | Zalutumumab in Non-curable Patients With SCCHN NCT00542308 | Genmab | Phase 2 |
| Completed | Study of Sorafenib/Cetuximab in Head and Neck Cancer NCT00815295 | Duke University | Phase 1 / Phase 2 |
| Completed | Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell NCT00661427 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy NCT00530283 | AHS Cancer Control Alberta | — |
| Completed | Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer NCT00485485 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer NCT00401401 | Genmab | Phase 1 / Phase 2 |
| Completed | Zalutumumab in Patients With Non-curable Head and Neck Cancer NCT00382031 | Genmab | Phase 3 |
| Completed | The IRESSA Novel Head and Neck Chemotherapy Evaluation Study NCT00255476 | AstraZeneca | Phase 2 |
| Terminated | RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus NCT00559351 | Ministry of Scientific Research and Information Technology, Poland | Phase 3 |
| Withdrawn | A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and NCT00363441 | Alberta Health services | Phase 2 / Phase 3 |